Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

About this update from Rocket Pharmaceuticals, Inc.

PRV monetization provides $180 million in non-dilutive capital to support cardiovascular pipeline Cash runway extended into the second quarter of 2028 CRANBURY, N.J., April 28, 2026--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced a strengthened financial position following the sale of its Rare Pediatric Disease Priority Review Voucher (PRV). Rocket has entered into a definitive agreement to sell its PRV for $180 million. The PRV was awarded following the U.S. Food and Drug Administration (FDA) accelerated approval of KRESLADI™ (marnetegragene autotemcel). The transaction reflects the continued strategic value of PRVs, as well as Rocket’s disciplined approach to capital formation and allocation in support of its prioritized cardiovascular gene therapy programs. "The monetization of our PRV, following the FDA approval of KRESLADI, provides meaningful non-dilutive capital and extends our cash runway into the second quarter of 2028," said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals. "This strengthens our ability to advance key clinical milestones across our cardiovascular gene therapy pipeline, with all programs on track." A Rare Pediatric Disease PRV is granted by the FDA to sponsors of approved therapies for certain rare pediatric diseases and may be used to obtain priority review for a subsequent marketing application or sold to another sponsor. The program was reauthorized in February 2026, extending the availability of vouchers for qualifying therapies and reinforcing its role as an incentive to support development of treatments for rare pediatric conditions. "We are deeply appreciative of the U.S. government’s continued recognition of the importance of therapeutic development for rare and often devastating pediatric disorders, which comprises an essential part of Rocket’s mission," Dr. Shah concluded. Proceeds from the transaction will support advancement of Rocket’s prioritized cardiovascular gene therapy pipeline, including clinical-stage programs in Danon disease, PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM), and BAG3-associated dilated cardiomyopathy (BAG3-DCM). Pro forma for this transaction, Rocket e...

View stock analysis, news, and events for Rocket Pharmaceuticals, Inc.